Alpha 2.0
Login Register
» Authors » K Battmer

K Battmer

Explore the profile of K Battmer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 144
Followers 0
Related Specialties
Hematology
Oncology
General Surgery
Top 10 Co-Authors
H Link
M Eder
A Ganser
L Arseniev
M Scherr
J G Kadar
I Sudmeier
W Stangel
A Stucki
H Poliwoda
Published In
Gene Ther
Infusionsther Transfusionsmed
Bone Marrow Transplant
Br J Haematol
Leukemia
Affiliations
Soon will be listed here.
Recent Articles
1.
Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia
Scherr M, Elder A, Battmer K, Barzan D, Bomken S, Ricke-Hoch M, et al.
Leukemia . 2013 Nov; 28(3):554-65. PMID: 24280866
Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the development of novel treatment strategies. As the known oncomir, miR-17~92, is regulated...
2.
Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover
Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, et al.
Oncogene . 2008 Apr; 27(34):4678-89. PMID: 18427551
Receptor tyrosine kinase-mediated signaling is tightly regulated by a number of cytoplasmic signaling molecules. In this report, we show that Bcr-Abl transformed chronic myelogenous leukemia (CML) cell lines, K562 and...
3.
Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy
Scherr M, Battmer K, Schultheis B, Ganser A, Eder M
Gene Ther . 2004 Dec; 12(1):12-21. PMID: 15602589
RNA interference (RNAi) has recently been used for sequence-specific gene silencing of disease-related genes including oncogenes in hematopoietic cells. To characterize its potential therapeutic value, we analyzed different modes to...
4.
Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction
Tiede A, Eder M, von Depka M, Battmer K, Luther S, Kiem H, et al.
Gene Ther . 2003 Sep; 10(22):1917-25. PMID: 14502221
Autologous transplantation of gene-modified hematopoietic stem cells may provide a therapeutic strategy for several monogeneic disorders. In previous studies, retroviral gene transfer of coagulation factor VIII (FVIII) into FVIII(-/-) mouse...
5.
Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography
Scherr M, Battmer K, Eder M, Schule S, Hohenberg H, Ganser A, et al.
Gene Ther . 2002 Nov; 9(24):1708-14. PMID: 12457285
Lentiviral vectors have been shown to stably transduce dividing and non-dividing target cells in vitro and in vivo. However, in vivo gene transfer applications with viral vectors in the central...
6.
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia
Hambach L, Eder M, Dammann E, Battmer K, Stucki A, Heil G, et al.
Bone Marrow Transplant . 2001 Nov; 28(7):705-7. PMID: 11704795
We report a patient with Ph-positive CML who developed a Ph-negative AML in donor cells 14 months after BMT from an HLA-identical male unrelated donor. The Ph translocation could not...
7.
Quantitative determination of lentiviral vector particle numbers by real-time PCR
Scherr M, Battmer K, Blomer U, Ganser A, Grez M
Biotechniques . 2001 Sep; 31(3):520, 522, 524, passim. PMID: 11570495
Here, we describe a quantitative, DNA-based, real-time PCR approach to determine the number of lentivirus particles that are present in vector preparations. In this approach, the minus strong-stop cDNA fragment...
8.
Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation
Eder M, Battmer K, Kafert S, Stucki A, Ganser A, Hertenstein B
Leukemia . 1999 Sep; 13(9):1383-9. PMID: 10482989
To analyze the value of real time RT-PCR for monitoring of bcr-abl expression in CML patients after allogeneic or autologous stem cell transplantation (SCT), we generated pairs of PCR-primers and...
9.
Technical and safety aspects of blood and marrow transplantation using G-CSF mobilized family donors
Kadar J, Arseniev L, Schnitger K, Sudmeier I, Zaki M, Battmer K, et al.
Transfus Sci . 1996 Nov; 17(4):611-8. PMID: 10168561
An allogeneic transplantation programme using immunoselected blood progenitor and bone marrow CD34+ cells has been established. Thirteen healthy HLA-matched, MLC negative sibling donors received two doses of 5 micrograms kg-1...
10.
[Ex vivo increase in hematopoietic progenitor cells for clinical use]
Arseniev L, Battmer K, Stucki A, Sudmeyer I, Kadar J, Martin M, et al.
Med Klin (Munich) . 1996 Apr; 91 Suppl 3:50-9. PMID: 8692120
Background: The clinical use of ex vivo expanded hematopoietic progenitor cells is currently explored. Material And Methods: In this study the culturing of G-CSF mobilized and purified CD34+ blood cells...